EPFL scientists have developed a chemical method for targeting the effects of cancer-fighting immunotherapy drugs only to the tumor tissue, making the drugs less toxic to the rest of the human body.
EPFL scientists propose a new way of understanding how the brain processes unconscious information into our consciousness. According to the model, consciousness arises only in time intervals of up to 400 milliseconds, with gaps of unconsciousness in between.
Swiss researchers of EPFL have harnessed the enzyme that makes fireflies glow to diagnose medical conditions. This technique is cheaper, simpler and more accurate than other methods.
Amazentis SA, an innovative life sciences company applying scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Medicine with the Ecole Polytechnique Federale Lausanne, demonstrating that the Company's lead product candidate, urolithin A, improves mitochondrial and muscle function, resulting in enhanced muscle strength and endurance during aging. Amazentis is presently evaluating urolithin A in a first human clinical trial with results expected in 2017.
In a cutting-edge treatment for Alzheimer's disease, EPFL scientists have developed an implantable capsule that can turn the patient's immune system against the disease.
By analyzing blood flow in the brain, a team of EPFL was able to observe the moment-to-moment interactions between different regions in the brain. Their new imaging technique could help with the early detection of Alzheimer’s disease.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
EPFL scientists have developed a chemical method for targeting the effects of cancer-fighting immunotherapy drugs only to the tumor tissue, making the drugs less toxic to the rest of the human body.